Article Versions Notes

Gulde S, Wiedemann T, Schillmaier M, Valença I, Lupp A, Steiger K, Yen H-Y, Bäuerle S, Notni J, Luque R, et al. Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers. 2021; 13(12):3097. https://doi.org/10.3390/cancers13123097

Gulde, Sebastian, Tobias Wiedemann, Mathias Schillmaier, Isabel Valença, Amelie Lupp, Katja Steiger, Hsi-Yu Yen, Stephen Bäuerle, Johannes Notni, Raul Luque, and et al. 2021. "Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors" Cancers 13, no. 12: 3097. https://doi.org/10.3390/cancers13123097

Gulde, S., Wiedemann, T., Schillmaier, M., Valença, I., Lupp, A., Steiger, K., Yen, H. -Y., Bäuerle, S., Notni, J., Luque, R., Schmid, H., Schulz, S., Ankerst, D. P., Schilling, F., & Pellegata, N. S. (2021). Gender-Specific Efficacy Revealed by Head-to-Head Comparison of Pasireotide and Octreotide in a Representative In Vivo Model of Nonfunctioning Pituitary Tumors. Cancers, 13(12), 3097. https://doi.org/10.3390/cancers13123097